Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Dow
Moodys
McKinsey
Fish and Richardson
Johnson and Johnson
Cerilliant
Queensland Health
Healthtrust

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021217

« Back to Dashboard

NDA 021217 describes EXALGO, which is a drug marketed by Specgx Llc and is included in one NDA. It is available from one supplier. Additional details are available on the EXALGO profile page.

The generic ingredient in EXALGO is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.
Summary for 021217
Tradename:EXALGO
Applicant:Specgx Llc
Ingredient:hydromorphone hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021217
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 021217
Suppliers and Packaging for NDA: 021217
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217 NDA AUTHORIZED GENERIC SpecGx LLC 0406-3308 0406-3308-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0406-3308-01)
EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217 NDA AUTHORIZED GENERIC SpecGx LLC 0406-3312 0406-3312-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0406-3312-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength8MG
Approval Date:Mar 1, 2010TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength12MG
Approval Date:Mar 1, 2010TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength16MG
Approval Date:Mar 1, 2010TE:ABRLD:Yes

Expired US Patents for NDA 021217

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Specgx Llc EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217-004 Aug 24, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Specgx Llc EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217-001 Mar 1, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Specgx Llc EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217-002 Mar 1, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Specgx Llc EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217-003 Mar 1, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Specgx Llc EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217-002 Mar 1, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Deloitte
AstraZeneca
Argus Health
Mallinckrodt
Covington
Johnson and Johnson
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.